AVTX vs NGNE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AVTX · Avalo Therapeutics$6.76 ▲ 0.15%
NGNE · Neurogene$22.15 ▼ 3.40%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AVTX -62.4%
- NGNE +8.4%
Head to head
| Metric | AVTX | NGNE |
|---|---|---|
| Price | $6.76 | $22.15 |
| Change today | ▲ 0.15% | ▼ 3.40% |
| Market cap | $390.88M | $458.53M |
| Return, 3 months | -64.9% | -44.1% |
| Return, year to date | -62.8% | +7.5% |
| Return, 1 year | -62.1% | +10.4% |
| P/E (TTM) | – | – |
| P/B | 0.9 | 1.3 |
| P/E percentile vs own 5y | 6th | 45th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +38.1% | -38.5% |
| Gross margin | – | – |
| Operating margin | -161,962.7% | – |
| Net margin | -150,259.3% | – |
| Return on equity | -33.6% | -38.4% |
| Analyst target vs. price | +284.6% | +309.3% |
| Analyst buy share | 71% | 100% |
| RSI (14) | 33 | 35 |
| 30-day volatility | 167.0% | 88.8% |
| Max drawdown, 1 year | -71.0% | -49.7% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NGNE is the largest of the group by market value.
- NGNE has returned the most over the past year.
- NGNE has been the calmest stock over the last 30 days.